<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="691">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01976806</url>
  </required_header>
  <id_info>
    <org_study_id>GM-023</org_study_id>
    <secondary_id>UL1RR025758-02</secondary_id>
    <nct_id>NCT01976806</nct_id>
  </id_info>
  <brief_title>The Effects of DHA on Periodontitis</brief_title>
  <acronym>DAP</acronym>
  <official_title>The Effects of Docosahexaenoic Acid on Periodontitis in Adults: A Pilot Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Center for Research Resources (NCRR)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Harvard Medical School</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Beth Israel Deaconess Medical Center</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether docosahexaenoic acid (DHA) is effective in
      the treatment of periodontitis in adults.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. The primary aim of this study is to investigate the effect of docosahexaenoic acid
           (DHA; 2 gm/day) plus low dose aspirin (ASA 81 mg/day)compared to ASA alone on
           periodontitis over three months. Our hypothesis is that DHA plus ASA will improve
           periodontitis as measured by objective periodontal exam, including decreased pocket
           depth (mm), gingival index (0-3), plaque index (0-3) and bleeding on probing (yes/no)
           compared to ASA alone.

        2. Assess the effect of DHA and ASA exposure on markers of local inflammation, including
           gingival crevicular fluid (GCF) CRP, IL-1 beta and IL-6 three months after exposure to
           DHA plus ASA compared to ASA alone.

        3. Evaluate potential mechanisms through changes in the periodontal microbial flora which
           may occur as a result of exposure to DHA and ASA compared to ASA alone. Our hypothesis
           is that there will be a substantial post therapy change in the microbial flora of
           dental plaques, favoring bacteria associated with a lower systemic inflammatory state.

        4. Assess the effect of DHA and ASA exposure on markers of systemic inflammation,
           including serum C-Reactive Protein (CRP), interleukin-6 (IL-6) and vascular adhesion
           molecule (VCAM) compared to ASA. Our hypothesis is that there will be a decrease in
           serum CRP, IL-6 and VCAM three months after exposure to DHA plus ASA compared to ASA
           alone.

        5. Assess the effect of DHA and ASA exposure on markers of systemic bone turnover,
           including urine N-terminal telopeptide (NTx) compared to ASA. Our hypothesis is that
           there will be a decrease in urine NTx three months after exposure to DHA plus ASA
           compared to ASA alone.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change in Pocket Depth (mm)</measure>
    <time_frame>Baseline and 3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Pocket probing depth (PD) is the depth a dental probe can be inserted into a gingival pocket at a particular site (6 sites per tooth) measured in millimeters among teeth with PD greater than or equal to 5 mm (N=533 dental sites total).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Gingival Index (0-3)</measure>
    <time_frame>Baseline and 3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Gingival Index (GI) is a measure of gingival inflammation, which is assigned a score (0-3).
Score Criteria:
0: No inflammation.
Mild inflammation, slight change in color, slight edema, no bleeding on probing.
Moderate inflammation, moderate glazing, redness, bleeding on probing.
Severe inflammation, marked redness and hypertrophy, ulceration, tendency to spontaneous bleeding.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Plaque Index (0-3)</measure>
    <time_frame>Baseline and 3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Plaque Index (PI) is a measure of gingival inflammation as induced by bacterial plaque deposition at and under the gum line.
Score Criteria:
0: No plaque
A film of plaque adhering to the free gingival margin and adjacent area of the tooth, which can not be seen with the naked eye. But only by using disclosing solution or by using probe.
Moderate accumulation of deposits within the gingival pocket, on the gingival margin and/ or adjacent tooth surface, which can be seen with the naked eye.
Abundance of soft matter within the gingival pocket and/or on the tooth and gingival margin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Bleeding on Probing (Yes/no)</measure>
    <time_frame>Baseline and 3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Bleeding On Probing (BOP) is a measure of gingival inflammation and tissue destruction, which describes whether or not bleeding at the dental pocket occurred following probing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gingival Crevicular Fluid High Sensitivity C-reactive Protein</measure>
    <time_frame>Baseline and 3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Gingival crevicular fluid (GCF) is the fluid bathing the teeth under the gum line. GCF samples were analyzed for high sensitivity C-reactive protein as a measure of local gingival inflammation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gingival Crevicular Fluid Interleukin-6</measure>
    <time_frame>Baseline and 3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Gingival crevicular fluid (GCF) samples were analyzed for Interleukin-6, which is a measure of local gingival inflammation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gingival Crevicular Fluid Interleukin-1 Beta</measure>
    <time_frame>Baseline and 3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Gingival crevicular fluid (GCF) samples were analyzed for Interleukin-1 beta, which is a measure of local gingival inflammation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum High-sensitivity C-reactive Protein</measure>
    <time_frame>Baseline and 3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Serum high-sensitivity C-reactive protein is a measure of systemic inflammation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum High-sensitivity Interleukin-6</measure>
    <time_frame>Baseline and 3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Serum high-sensitivity interleukin-6 is a measure of systemic inflammation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Soluble Vascular Cell Adhesion Molecule</measure>
    <time_frame>Baseline and 3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Serum soluble vascular cell adhesion molecule (VCAM) is a measure of systemic inflammation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine N-Terminal Telopeptides</measure>
    <time_frame>Baseline and 3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Urine N-Terminal Telopeptides are a measure of systemic bone turnover.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in Red Blood Cell Membrane Docosahexaenoic Acid</measure>
    <time_frame>Baseline and 3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Red blood cell phospholipid fatty acids were measured at baseline and 3-month follow up as a measure of adherence.</description>
  </other_outcome>
  <other_outcome>
    <measure>Vital Signs</measure>
    <time_frame>Baseline and 3 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Baseline and follow-up vital signs, including temperature, blood pressure, heart rate were measured to assess for safety and eligibility (uncontrolled hypertensives were excluded).</description>
  </other_outcome>
  <other_outcome>
    <measure>Serum Fasting Lipid Profile</measure>
    <time_frame>Baseline and 3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Baseline and follow-up fasting lipid profiles were measured for descriptive purposes of our study population.</description>
  </other_outcome>
  <other_outcome>
    <measure>Serum Complete Blood Count</measure>
    <time_frame>Baseline and 3 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Baseline and 3 month follow-up complete blood counts were measured for descriptive purposes of our study population and for safety.</description>
  </other_outcome>
  <other_outcome>
    <measure>Urine Beta-human Chorionic Gonadotropin</measure>
    <time_frame>Baseline</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Urine beta-human chorionic gonadotropin was measured in all female subjects for eligibility (pregnant females excluded for safety).</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">55</enrollment>
  <condition>Periodontitis</condition>
  <condition>Gingivitis</condition>
  <condition>Inflammation</condition>
  <arm_group>
    <arm_group_label>Aspirin &amp; Docosahexaenoic acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aspirin 81 mg 1 tablet by mouth daily and Docosahexanoic acid (DHA) 500 mg 4 capsules by mouth daily (total daily dose of 2 grams DHA) for 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aspirin &amp; Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Aspirin 81 mg by mouth daily and placebo (50% corn oil/50% soybean oil) 4 capsules by mouth daily for 3 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <arm_group_label>Aspirin &amp; Docosahexaenoic acid</arm_group_label>
    <arm_group_label>Aspirin &amp; Placebo</arm_group_label>
    <other_name>Baby Aspirin</other_name>
    <other_name>Low Dose Aspirin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docosahexaenoic acid</intervention_name>
    <arm_group_label>Aspirin &amp; Docosahexaenoic acid</arm_group_label>
    <other_name>DHA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (for Docosahexaenoic acid)</intervention_name>
    <description>Placebo (corn/soybean oil) capsules manufactured to look identical to DHA capsules</description>
    <arm_group_label>Aspirin &amp; Placebo</arm_group_label>
    <other_name>50% corn oil/50% soybean oil</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age &gt;40 years

          -  &gt;20 natural teeth (excluding third molars)

          -  no orthodontic appliances

          -  periodontitis defined as &gt;4 teeth with pocket probing depths &gt;5 mm

        Exclusion Criteria:

          -  pregnancy

          -  diabetes

          -  severe chronic diseases

          -  gastrointestinal bleeding

          -  uncontrolled chronic diseases

          -  autoimmune disorders

          -  conditions requiring antibiotic prophylaxis

          -  warfarin

          -  clopidogrel

          -  antimicrobial therapy within 30 days

          -  chronic use of non-steroidal anti-inflammatory drugs (other than aspirin)

          -  omega-3 fatty acid use within 6 months

          -  loose teeth

          -  painful teeth

          -  periodontal abscess

          -  pocket depths &gt;10 mm in &gt;1 tooth

          -  periodontal therapy within the past two years

          -  allergy to aspirin

          -  allergy to fish oil

          -  allergy to corn oil

          -  allergy to soybean oil
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Asghar Z Naqvi, MD, MPH, MNS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beth Israel Deaconess Medical Center; Harvard Medical School</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kenneth J Mukamal, MD, MPH, MA</last_name>
    <role>Study Chair</role>
    <affiliation>Beth Israel Deaconess Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Naqvi AZ, Buettner C, Phillips RS, Davis RB, Mukamal KJ. n-3 fatty acids and periodontitis in US adults. J Am Diet Assoc. 2010 Nov;110(11):1669-75. doi: 10.1016/j.jada.2010.08.009.</citation>
    <PMID>21034880</PMID>
  </reference>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>February 23, 2014</lastchanged_date>
  <firstreceived_date>October 30, 2013</firstreceived_date>
  <firstreceived_results_date>December 3, 2013</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beth Israel Deaconess Medical Center</investigator_affiliation>
    <investigator_full_name>Asghar Naqvi</investigator_full_name>
    <investigator_title>Instructor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Docosahexaenoic acid</keyword>
  <keyword>DHA</keyword>
  <keyword>Periodontitis</keyword>
  <keyword>Gingivitis</keyword>
  <keyword>Omega-3 fatty acid</keyword>
  <keyword>Fish oil</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Gingivitis</mesh_term>
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Periodontitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Aspirin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Aspirin &amp; Docosahexaenoic Acid</title>
          <description>Aspirin 81 mg 1 tablet by mouth daily and Docosahexanoic acid (DHA) 500 mg 4 capsules by mouth daily (total daily dose of 2 grams DHA) for 3 months
Aspirin
Docosahexaenoic acid</description>
        </group>
        <group group_id="P2">
          <title>Aspirin &amp; Placebo</title>
          <description>Aspirin 81 mg by mouth daily and placebo (50% corn oil/50% soybean oil) 4 capsules by mouth daily for 3 months
Aspirin
Placebo (for Docosahexaenoic acid): Placebo (corn/soybean oil) capsules manufactured to look identical to DHA capsules</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Includes all subjects that completed follow-up</population>
      <group_list>
        <group group_id="B1">
          <title>Aspirin &amp; Docosahexaenoic Acid</title>
          <description>Aspirin 81 mg 1 tablet by mouth daily and Docosahexanoic acid (DHA) 500 mg 4 capsules by mouth daily (total daily dose of 2 grams DHA) for 3 months
Aspirin
Docosahexaenoic acid</description>
        </group>
        <group group_id="B2">
          <title>Aspirin &amp; Placebo</title>
          <description>Aspirin 81 mg by mouth daily and placebo (50% corn oil/50% soybean oil) 4 capsules by mouth daily for 3 months
Aspirin
Placebo (for Docosahexaenoic acid): Placebo (corn/soybean oil) capsules manufactured to look identical to DHA capsules</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="24"/>
                <measurement group_id="B2" value="22"/>
                <measurement group_id="B3" value="46"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="53" spread="8"/>
                <measurement group_id="B2" value="57" spread="8"/>
                <measurement group_id="B3" value="55" spread="8"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="11"/>
                <measurement group_id="B2" value="10"/>
                <measurement group_id="B3" value="21"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="13"/>
                <measurement group_id="B2" value="12"/>
                <measurement group_id="B3" value="25"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>American Indian or Alaska Native</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Asian</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="4"/>
                <measurement group_id="B2" value="1"/>
                <measurement group_id="B3" value="5"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Native Hawaiian or Other Pacific Islander</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Black or African American</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="7"/>
                <measurement group_id="B2" value="8"/>
                <measurement group_id="B3" value="15"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>White</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="12"/>
                <measurement group_id="B2" value="12"/>
                <measurement group_id="B3" value="24"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>More than one race</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="1"/>
                <measurement group_id="B3" value="1"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Unknown or Not Reported</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="1"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Smoking Status</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Current</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
                <measurement group_id="B2" value="1"/>
                <measurement group_id="B3" value="2"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Former</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="7"/>
                <measurement group_id="B2" value="6"/>
                <measurement group_id="B3" value="13"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Never</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="16"/>
                <measurement group_id="B2" value="15"/>
                <measurement group_id="B3" value="31"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>BMI (kg/m2)</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Normal (18.5-24.9 kg/m2)</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="9"/>
                <measurement group_id="B2" value="5"/>
                <measurement group_id="B3" value="14"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Overweight (25-30 kg/m2)</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="4"/>
                <measurement group_id="B2" value="10"/>
                <measurement group_id="B3" value="14"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Obese (&gt;30 kg/m2)</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="11"/>
                <measurement group_id="B2" value="7"/>
                <measurement group_id="B3" value="18"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Hypertension</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Hypertension</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="4"/>
                <measurement group_id="B2" value="6"/>
                <measurement group_id="B3" value="10"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>No Hypertension</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="20"/>
                <measurement group_id="B2" value="16"/>
                <measurement group_id="B3" value="36"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Hyperlipidemia</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Hyperlipidemia</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="5"/>
                <measurement group_id="B2" value="4"/>
                <measurement group_id="B3" value="9"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>No Hyperlipidemia</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="19"/>
                <measurement group_id="B2" value="18"/>
                <measurement group_id="B3" value="37"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Pocket Depth (mm)</title>
        <description>Pocket probing depth (PD) is the depth a dental probe can be inserted into a gingival pocket at a particular site (6 sites per tooth) measured in millimeters among teeth with PD greater than or equal to 5 mm (N=533 dental sites total).</description>
        <time_frame>Baseline and 3 months</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Aspirin &amp; Docosahexaenoic Acid</title>
            <description>Aspirin 81 mg 1 tablet by mouth daily and Docosahexanoic acid (DHA) 500 mg 4 capsules by mouth daily (total daily dose of 2 grams DHA) for 3 months
Aspirin
Docosahexaenoic acid</description>
          </group>
          <group group_id="O2">
            <title>Aspirin &amp; Placebo</title>
            <description>Aspirin 81 mg by mouth daily and placebo (50% corn oil/50% soybean oil) 4 capsules by mouth daily for 3 months
Aspirin
Placebo (for Docosahexaenoic acid): Placebo (corn/soybean oil) capsules manufactured to look identical to DHA capsules</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="24"/>
                  <measurement group_id="O2" value="22"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change in Pocket Depth (mm)</title>
            <description>Pocket probing depth (PD) is the depth a dental probe can be inserted into a gingival pocket at a particular site (6 sites per tooth) measured in millimeters among teeth with PD greater than or equal to 5 mm (N=533 dental sites total).</description>
            <units>mm</units>
            <param>Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-0.71" spread="0.07"/>
                  <measurement group_id="O2" value="-0.54" spread="0.07"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Intent-to-treat basis with a type I error rate of 0.05. The follow-up pocket depth, was assessed in linear mixed effects models with a compound-symmetry covariance structure and age, sex, BMI, race, baseline pocket depth, baseline red blood cell (RBC) DHA level (dichotomized at median), and intervention group as fixed-effect variables.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.05</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Compound-symmetry covariance structure with age, sex, BMI, race, baseline pocket depth, baseline RBC DHA level, and intervention group variables</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.29</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.13</dispersion_value>
            <estimate_desc>Mean change in pocket depth (3-month follow-up minus baseline) among dental sites with baseline pocket depths &gt;=5 mm in the DHA intervention group versus the placebo group.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Gingival Index (0-3)</title>
        <description>Gingival Index (GI) is a measure of gingival inflammation, which is assigned a score (0-3).
Score Criteria:
0: No inflammation.
Mild inflammation, slight change in color, slight edema, no bleeding on probing.
Moderate inflammation, moderate glazing, redness, bleeding on probing.
Severe inflammation, marked redness and hypertrophy, ulceration, tendency to spontaneous bleeding.</description>
        <time_frame>Baseline and 3 months</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Plaque Index (0-3)</title>
        <description>Plaque Index (PI) is a measure of gingival inflammation as induced by bacterial plaque deposition at and under the gum line.
Score Criteria:
0: No plaque
A film of plaque adhering to the free gingival margin and adjacent area of the tooth, which can not be seen with the naked eye. But only by using disclosing solution or by using probe.
Moderate accumulation of deposits within the gingival pocket, on the gingival margin and/ or adjacent tooth surface, which can be seen with the naked eye.
Abundance of soft matter within the gingival pocket and/or on the tooth and gingival margin.</description>
        <time_frame>Baseline and 3 months</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Bleeding on Probing (Yes/no)</title>
        <description>Bleeding On Probing (BOP) is a measure of gingival inflammation and tissue destruction, which describes whether or not bleeding at the dental pocket occurred following probing.</description>
        <time_frame>Baseline and 3 months</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Gingival Crevicular Fluid High Sensitivity C-reactive Protein</title>
        <description>Gingival crevicular fluid (GCF) is the fluid bathing the teeth under the gum line. GCF samples were analyzed for high sensitivity C-reactive protein as a measure of local gingival inflammation.</description>
        <time_frame>Baseline and 3 months</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Gingival Crevicular Fluid Interleukin-6</title>
        <description>Gingival crevicular fluid (GCF) samples were analyzed for Interleukin-6, which is a measure of local gingival inflammation.</description>
        <time_frame>Baseline and 3 months</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Gingival Crevicular Fluid Interleukin-1 Beta</title>
        <description>Gingival crevicular fluid (GCF) samples were analyzed for Interleukin-1 beta, which is a measure of local gingival inflammation.</description>
        <time_frame>Baseline and 3 months</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum High-sensitivity C-reactive Protein</title>
        <description>Serum high-sensitivity C-reactive protein is a measure of systemic inflammation.</description>
        <time_frame>Baseline and 3 months</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum High-sensitivity Interleukin-6</title>
        <description>Serum high-sensitivity interleukin-6 is a measure of systemic inflammation.</description>
        <time_frame>Baseline and 3 months</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Soluble Vascular Cell Adhesion Molecule</title>
        <description>Serum soluble vascular cell adhesion molecule (VCAM) is a measure of systemic inflammation.</description>
        <time_frame>Baseline and 3 months</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Urine N-Terminal Telopeptides</title>
        <description>Urine N-Terminal Telopeptides are a measure of systemic bone turnover.</description>
        <time_frame>Baseline and 3 months</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Red Blood Cell Membrane Docosahexaenoic Acid</title>
        <description>Red blood cell phospholipid fatty acids were measured at baseline and 3-month follow up as a measure of adherence.</description>
        <time_frame>Baseline and 3 months</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Vital Signs</title>
        <description>Baseline and follow-up vital signs, including temperature, blood pressure, heart rate were measured to assess for safety and eligibility (uncontrolled hypertensives were excluded).</description>
        <time_frame>Baseline and 3 months</time_frame>
        <safety_issue>Yes</safety_issue>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Serum Fasting Lipid Profile</title>
        <description>Baseline and follow-up fasting lipid profiles were measured for descriptive purposes of our study population.</description>
        <time_frame>Baseline and 3 months</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Serum Complete Blood Count</title>
        <description>Baseline and 3 month follow-up complete blood counts were measured for descriptive purposes of our study population and for safety.</description>
        <time_frame>Baseline and 3 months</time_frame>
        <safety_issue>Yes</safety_issue>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Urine Beta-human Chorionic Gonadotropin</title>
        <description>Urine beta-human chorionic gonadotropin was measured in all female subjects for eligibility (pregnant females excluded for safety).</description>
        <time_frame>Baseline</time_frame>
        <safety_issue>Yes</safety_issue>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>DHA 2 gm (4 Caps) + Aspirin 81 mg (1 Tablet by Mouth Per Day)</title>
        </group>
        <group group_id="E2">
          <title>Placebo (4 Caps) + Aspirin 81 mg (1 Tablet by Mouth Per Day)</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Gingival bleeding while flossing</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Intermittent palpitations</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Melena</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>GERD</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Chipped tooth</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Diaphoresis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Cavity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Verbally abusive toward staff</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Asghar Naqvi</name_or_title>
      <organization>Beth Israel Deaconess Medical Center</organization>
      <phone>617-667-2117</phone>
      <email>anaqvi@bidmc.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
